2029041828

From: RPAGES --VUS0212A Date and time 09/24/93 11:39:29
To: RDEMPSEY--VCH0021A Ruth Dempsey BVIOL --VCH0021A Wolf Reininghaus

From: Robert A. Pages
Subject: IARC plng recap

*** Forwarding note from MWINOKUR--VUS0212A 09/24/93 08:52 ***
To: HREIF --VCH0021A Helmut Reif MLOGUE --VUS0212A Mayada Logue
RCARCHMA--VUS0212A Richard Carchman GPATSKAN--VUS0212A George Patskan
RPAGES --VUS0212A Robert Pages
cc: DGREENBE--VCH0021A D. Greenberg JSULLIVA--VCH0021A
HLYBEROP--VCH0021A DBUSHONG--VCH0021A David Bushong
AANDRADE--VCH0021A Anthony Andrade AREIMAN --VCH0021A Andre Reiman
JGOODHEA--VUS0212A Goodheart,Jan MLOGUE --VUS0212A Mayada Logue
MPOTTORF--VUS0212A Pottorff,Mary TLATTANZ--DSVPMUSA T LATTANZIO

From: Matthew Winokur
Subject: IARC plng recap

Following is a recap of the commitments agreed to at yesterday's meeting regarding planning the scientific intelligence gathering and assessment of the IARC study.

It was agreed that Helmut would be the overall coordinator of the science effort which will include:

o Obtain and assess (internally and perhaps with outside resources, e.g., Peter Lee) the latest version of the survey questionnaire being used in the study;

o Undertake preemptive assessment of the questionnaire to expose weaknesses. Does it fail to account for confounders, adducts, cotinine measurement, breast cancer metastisis and general weaknesses inherent in questionnaire-based studies.

o Assess the work on ETS and epidemiology by each of the study country collaborators in order to gauge their attitudes on ETS and epi methodology. (See PM/SH&B/C&B "team" noted below)

o Prepare literature review on ETS and, especially epi methodology, with a Euro-focus to prepare grounds for citing potential weakness in IARC study. What do European scientists say is necessary to do good epidemiology and has IARC complied.

o Evaluate other IARC studies, which might be analagous to the ETS study, to ascertain how IARC has undertaken them with special emphasis on application of criteria for conducting epidemiology.

o Obtain IARC criteria for conducting epi studies.

o Organize with SH&B (Andrade) and C&B (Lister) a team to identify and mobilize consultants who can provide insights into the 11 individual country studies. Tony will provide legal oversight.This effort would also help prepare science responses in key markets when the study is released.

o Evaluate feasibility and timing of offering IARC the Hazeltine exposure study results and, possibly, the Matinowski study protocols. Ideally, this would be done via Dr. Eisenberg at CIAR.

o Evaluate feasibility of supporting a conference in Europe on epi protocols with special emphasis on need to factor confounders. (It appears the IARC questionnaire fails to consider confounders adequately.)

Best regards,

2029041828.A

Source: https://www.industrydocuments.ucsf.edu/docs/jnjx0000